Patents by Inventor Donald Rao
Donald Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9157084Abstract: Compositions and methods to attenuate the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs was substituted therefor described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: GrantFiled: December 20, 2010Date of Patent: October 13, 2015Assignee: GRADALIS, INC.Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 9132146Abstract: Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: GrantFiled: December 20, 2010Date of Patent: September 15, 2015Assignee: GRADALIS, INC.Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 9133459Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.Type: GrantFiled: December 4, 2012Date of Patent: September 15, 2015Assignees: Strike Bio, Inc., Baylor College of MedicineInventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi
-
Publication number: 20150086619Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: obtaining a specimen of cancer tissue and normal tissue from a patient; extracting total protein; obtaining a protein expression profile; identifying over-expressed proteins; comparing the protein expression profile to a gene expression profile; identifying at least one prioritized protein target; designing a first RNA interference expression cassette; designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding; incorporating the first cassette into a delivery vehicle; and providing a patient with an effective amount of the first delivery vehicle.Type: ApplicationFiled: November 7, 2014Publication date: March 26, 2015Inventors: David M. Shanahan, John J. Nemunaitis, I, Neil Senzer, Phillip B. Maples, Donald Rao
-
Publication number: 20150004691Abstract: The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.Type: ApplicationFiled: June 27, 2014Publication date: January 1, 2015Inventor: Donald Rao
-
Patent number: 8916530Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: (a) obtaining a specimen of cancer tissue and normal tissue from a patient; (b) extracting total protein and RNA from the cancer tissue and normal tissue; (c) obtaining a protein expression profile of the cancer tissue and normal tissue; (d) identifying over-expressed proteins in the cancer tissue; (e) comparing the protein expression profile to a gene expression profile; (f) identifying at least one prioritized protein target by assessing connectivity of each said over-expressed protein to other cancer-related or stimulatory proteins; (g) designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding the prioritized target protein; (h): designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding a protein of higher priority in the signaling pathway in which the first protein is a component; (i) incorporating the first cassType: GrantFiled: October 30, 2009Date of Patent: December 23, 2014Assignee: Gradalis, Inc.Inventors: David Shanahan, John Nemunaitis, Neil Senzer, Phillip Maples, Donald Rao
-
Patent number: 8906874Abstract: The present invention includes bifunctional shRNAs capable of reducing an expression of a Stathmin 1 gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Stathmin 1 gene, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Stathmin 1.Type: GrantFiled: March 1, 2012Date of Patent: December 9, 2014Assignee: Gradalis, Inc.Inventors: Donald Rao, John J. Nemunaitis, Neil Senzer
-
Publication number: 20140242639Abstract: A method for designing a bi-shRNA expression cassette encoding a bi-shRNA comprising: selecting one or more target site sequences; providing a backbone sequence comprising a first and a second stem-loop structure, inserting a first passenger strand and a second passenger strand and providing for synthesis of the bi-shRNA expression cassette.Type: ApplicationFiled: May 6, 2014Publication date: August 28, 2014Applicant: Gradalis, Inc.Inventor: Donald Rao
-
Patent number: 8808983Abstract: The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.Type: GrantFiled: June 29, 2012Date of Patent: August 19, 2014Assignee: Gradalis, Inc.Inventor: Donald Rao
-
Patent number: 8758998Abstract: A method for designing a bi-shRNA expression cassette encoding a bi-shRNA comprising: selecting one or more target site sequences; providing a backbone sequence comprising a first and a second stem-loop structure, inserting a first passenger strand and a second passenger strand and providing for synthesis of the bi-shRNA expression cassette.Type: GrantFiled: February 1, 2012Date of Patent: June 24, 2014Assignee: Gradalis, Inc.Inventor: Donald Rao
-
Patent number: 8735058Abstract: The present invention relates to certain novel shRNA molecules and methods of use thereof. According to certain embodiments of the present invention, methods for reducing the expression level of a target gene are provided. Such methods generally comprise providing a cell with one or more precursor nucleic acid sequences that encode two or more RNA molecules. A first RNA molecule comprises a double stranded sequence, which includes a guide strand sequence that is complementary to a portion of an mRNA transcript encoded by the target gene. In addition, a second RNA molecule comprises a second double stranded sequence, which includes a second guide strand sequence that is partially complementary to a portion of the mRNA transcript encoded by the target gene. Preferably, the second guide strand sequence comprises one or more bases that are mismatched with a nucleic acid sequence of the mRNA transcript encoded by the target gene.Type: GrantFiled: June 29, 2012Date of Patent: May 27, 2014Assignee: Gradalis, Inc.Inventor: Donald Rao
-
Publication number: 20140134236Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding sType: ApplicationFiled: November 4, 2013Publication date: May 15, 2014Applicant: Gradalis, Inc.Inventors: David Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 8603991Abstract: Methods for treating cancer that include (a) obtaining a specimen of cancer issue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue; (c) extracting total protein from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue; (e) identifying a group of proteins that are expressed in the cancer tissue at significantly different levels than in the normal tissue; (f) identifying one or more prioritized proteins from the group of proteins, which will serve as the target for an RNA interference molecule (RNAi), which, when provided to a patient, will reduce the expression level of the one or more prioritized proteins using both cleavage-dependent and cleavage-independent pathways of the RNA-induced silencing complex (RISC).Type: GrantFiled: November 17, 2006Date of Patent: December 10, 2013Assignee: Gradalis, Inc.Inventors: David Shanahan, John Nemunaitis, Neil Senzer, Phillip Maples, Donald Rao
-
Publication number: 20130302407Abstract: The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras.Type: ApplicationFiled: May 9, 2013Publication date: November 14, 2013Applicant: GRADALIS, Inc.Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neal Senzer
-
Publication number: 20130295160Abstract: A miR-196a antagonist capable of inhibiting a miR-196a activity, the miR-196a antagonist comprising one or more target sites for miR-196a. Included is also an expression vector comprising a promoter and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more miR-196a antagonists capable of inhibiting a miR-196a activity. In one example, the one or more miR-196a antagonists comprise at least one stem-loop structure comprising a guide strand that comprises a sequence that is complementary to miR-196a, the stem-loop structure further comprising a passenger strand that comprises a mismatch.Type: ApplicationFiled: January 10, 2013Publication date: November 7, 2013Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Changyi Chen, Qizhi Yao
-
Publication number: 20130266639Abstract: The present invention includes compositions and methods treating triple negative breast cancer comprising administering a therapeutically effective amount of a formulation that includes vector that expresses an SRC-1-specific bifunctional shRNA, an SRC-3-specific bifunctional shRNA, or both, to impair triple negative breast cancer cell growth.Type: ApplicationFiled: June 13, 2013Publication date: October 10, 2013Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neil Senzer, Bert W. O'Malley, David Lonard
-
Publication number: 20130259927Abstract: The present invention includes compositions and methods of making and using an imaging label comprising an expression vector comprising a promoter; and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of inhibiting an expression of a target gene sequence that is a EWS-FLI1 fusion gene, a EWSR1-ERG fusion gene, or both in Ewing's sarcoma via RNA interference; wherein the one or more shRNA comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the target gene.Type: ApplicationFiled: April 2, 2013Publication date: October 3, 2013Applicant: Gradalis, Inc.Inventors: John J. Nemunaitis, Donald Rao, Neil Senzer
-
Publication number: 20130259926Abstract: The present invention includes bifunctional shRNAs capable of reducing an expression of a Mesothelin gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Mesothelin, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Mesothelin.Type: ApplicationFiled: March 28, 2013Publication date: October 3, 2013Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neil Senzer, Qizhi Yao, Changyi (Johnny) Chen, F. Charles Brunicardi
-
Publication number: 20130259925Abstract: The present invention includes compositions and methods of making and using an expression vector comprising a promoter and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of inhibiting an expression of a SRC-3 gene via RNA interference, wherein the one or more shRNA comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the SRC-3.Type: ApplicationFiled: March 27, 2013Publication date: October 3, 2013Applicants: BAYLOR COLLEGE OF MEDICINE, GRADALIS, INC.Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neil Senzer, Bert W. O'Malley, David Lonard
-
Publication number: 20130084331Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.Type: ApplicationFiled: December 4, 2012Publication date: April 4, 2013Applicants: BAYLOR COLLEGE OF MEDICINE, GRADALIS, INC.Inventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi